title: [Interferon therapy in liver cirrhosis].
abstract: Ten patients were given 3MU/3 times/week of r-interferon alpha 2b for 4 months; six patients were given 1MU/3 times/week for 4 months. The choice of these regimes has been based on the number of platelets. Among the patients treated with 9MU/week we observed a type I response (alanine-aminotransferases normalization) in 40% of cases, a type II (ALT fifty percent reduction) in 40% of cases, and a type III (no response) in 20% of cases. Among the patients treated with 3MU/week we observed a type II response in 16.7% and a type III in 83.3% of cases. Treatment of Child A liver cirrhosis with r-interferon demonstrates to rise, therefore, the same percentage of response which are obtained in the treatment of chronic active hepatitis, when the same doses are administered (9MU/week).
authors: Divisione di Gastroenterologia ed Endoscopia Digestiva, Ospedale San Martino, Genova.
authors: A
authors: A
authors: Perasso
authors: G
authors: G
authors: Testino
mesh_terms: D000368:Aged; D000410:Alanine Transaminase / Q000097:blood; D004306:Dose-Response Relationship, Immunologic; D004341:Drug Evaluation; D005260:Female; D006526:Hepatitis C / Q000150:complications / Q000201:enzymology / Q000628:therapy; D006801:Humans; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000008:administration & dosage*; D008103:Liver Cirrhosis / Q000201:enzymology / Q000209:etiology / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D011994:Recombinant Proteins; D013997:Time Factors
chemical_list: D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins; D000410:Alanine Transaminase
vernacular_title: Terapia con interferon nella cirrosi epatica.